Celecoxib/Lisinopril

塞来昔布/赖诺普利

Report date: 2022/03/03 15:55:47

Base Information

Drug NameCelecoxib/Lisinopril
Drug Alias Name塞来昔布+赖诺普利Celecoxib/lisinopril - Adhera Therapeutics赖诺普利+塞来昔布Lisinopril/CelecoxibLisinopril+Celecoxib +[8] 
ClassificationSmall molecules
Mechanisms of ActionCyclooxygenase-2 inhibitorsAngiotensin-converting enzyme inhibitors
TargetsCyclooxygenase-2Angiotensin-converting enzyme
Therapy Area/IndicationsHypertensionArthritis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsYes LisinoprilCelecoxib
Global Highest StatusClinical
Highest Status in ChinaN/A
Originator CompaniesAutotelic
China Registration ClassN/A

Develop Information

Active CompaniesAutotelic
Inactive CompaniesN/A
Active IndicationsHypertensionArthritis
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A